Characteristics and outcomes of patients hospitalized for heart failure in the United States: Rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE)Kirkwood F. Adams, Darlene P. Horton, Gregg C. Fonarow et al.|American Heart Journal|2005Cited by 2.1k
Intravenous Nesiritide, a Natriuretic Peptide, in the Treatment of Decompensated Congestive Heart FailureWilson S. Colucci, Thierry H. LeJemtel, Darlene P. Horton et al.|New England Journal of Medicine|2000Cited by 908
Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: The PRECEDENT studyAndrew J. Burger, Uri Elkayam, Darlene P. Horton et al.|American Heart Journal|2002Cited by 323
Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failureRoger M. Mills, Kanu Chatterjee, Thierry H. LeJemtel et al.|Journal of the American College of Cardiology|1999Cited by 323
Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure.Stephen S. Gottlieb, M. Dekock, Kenneth Dickstein et al.|Circulation|1993Cited by 292